Piper Sandler Reiterates Neutral on Xeris Biopharma Holdings, Raises Price Target to $12
Benzinga Newsdesk 9 hours ago
Analyst RatingsNewsReiterationPrice Target
Piper Sandler analyst David Amsellem reiterates Xeris Biopharma Holdings (NASDAQ:XERS) with a Neutral and raises the price target from $8 to $12.
Piper Sandler analyst David Amsellem reiterates Xeris Biopharma Holdings (NASDAQ:XERS) with a Neutral and raises the price target from $8 to $12.